BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 15120805)

  • 1. Cardiology management improves secondary prevention measures among patients with coronary artery disease.
    Ho PM; Masoudi FA; Peterson ED; Grunwald GK; Sales AE; Hammermeister KE; Rumsfeld JS
    J Am Coll Cardiol; 2004 May; 43(9):1517-23. PubMed ID: 15120805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low levels of low-density lipoprotein cholesterol and blood pressure and progression of coronary atherosclerosis.
    Chhatriwalla AK; Nicholls SJ; Wang TH; Wolski K; Sipahi I; Crowe T; Schoenhagen P; Kapadia S; Tuzcu EM; Nissen SE
    J Am Coll Cardiol; 2009 Mar; 53(13):1110-5. PubMed ID: 19324254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guideline-oriented ambulatory lipid-lowering therapy of patients at high risk for cardiovascular events by cardiologists in clinical practice: the 2L cardio registry.
    Gitt AK; Juenger C; Jannowitz C; Karmann B; Senges J; Bestehorn K
    Eur J Cardiovasc Prev Rehabil; 2009 Aug; 16(4):438-44. PubMed ID: 19369876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial).
    Goldenberg I; Benderly M; Sidi R; Boyko V; Tenenbaum A; Tanne D; Behar S
    Am J Cardiol; 2009 Jan; 103(1):41-5. PubMed ID: 19101227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost of lipid lowering in patients with coronary artery disease by case method learning.
    Kiessling A; Zethraeus N; Henriksson P
    Int J Technol Assess Health Care; 2005; 21(2):180-6. PubMed ID: 15921057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
    Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impaired intravascular triglyceride lipolysis constitutes a marker of clinical outcome in patients with stable angina undergoing secondary prevention treatment: a long-term follow-up study.
    Sposito AC; Lemos PA; Santos RD; Hueb W; Vinagre CG; Quintella E; Carneiro O; Chapman MJ; Ramires JA; Maranhão RC
    J Am Coll Cardiol; 2004 Jun; 43(12):2225-32. PubMed ID: 15193684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-density lipoprotein (LDL), which includes apolipoprotein A-I (apoAI-LDL) as a novel marker of coronary artery disease.
    Ogasawara K; Mashiba S; Hashimoto H; Kojima S; Matsuno S; Takeya M; Uchida K; Yajima J
    Clin Chim Acta; 2008 Nov; 397(1-2):42-7. PubMed ID: 18691566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of patients discharged from pharmacy-managed cardiovascular disease management.
    Olson KL; Delate T; Rasmussen J; Humphries TL; Merenich JA;
    Am J Manag Care; 2009 Aug; 15(8):497-503. PubMed ID: 19670953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment and secondary prevention of ischemic coronary events in Croatia (TASPIC-CRO study).
    Reiner Z; Mihatov S; Milicić D; Bergovec M; Planinc D;
    Eur J Cardiovasc Prev Rehabil; 2006 Aug; 13(4):646-54. PubMed ID: 16874158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for coronary artery disease in patients with elevated high-density lipoprotein cholesterol.
    DeFaria Yeh D; Freeman MW; Meigs JB; Grant RW
    Am J Cardiol; 2007 Jan; 99(1):1-4. PubMed ID: 17196452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reaching recommended lipid and blood pressure targets with amlodipine/atorvastatin combination in patients with coronary heart disease.
    Dorval JF; Anderson T; Buithieu J; Chan S; Hutchison S; Huynh T; Jobin J; Lonn E; Poirier P; Title L; Walling A; Tran T; Boudreau G; Charbonneau F; Genest J
    Am J Cardiol; 2005 Jan; 95(2):249-53. PubMed ID: 15642561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A managed care organization's use of integrated health management to improve secondary prevention of coronary artery disease.
    Berthiaume JT; Davis J; Taira DA; Thein KK
    Am J Manag Care; 2007 Mar; 13(3):142-7. PubMed ID: 17335357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-high-density lipoprotein cholesterol in secondary prevention of coronary artery disease: a unique risk factor or redundant information?
    Holcombe SM; Brubaker PH
    J Cardiopulm Rehabil Prev; 2007; 27(6):386-9. PubMed ID: 18197073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prognostic value of high-density lipoproteins in the cardiology unit].
    Sampietro T; Bigazzi F; Dal Pino B; Landi P; Puntoni M; Minichilli F; Bianchi F; Chella E; Carpeggiani C; Bionda A
    Ital Heart J Suppl; 2004 Sep; 5(9):720-6. PubMed ID: 15568610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cholesterol end points predict outcome in patients with coronary disease: quality improvement metrics from the enhancing secondary prevention in coronary artery disease (ESP-CAD) trial.
    McAlister FA; Majumdar SR; Lin M; Bakal J; Fradette M; Anderson T
    Can J Cardiol; 2014 Dec; 30(12):1627-32. PubMed ID: 25307535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol.
    Alsheikh-Ali AA; Lin JL; Abourjaily P; Ahearn D; Kuvin JT; Karas RH
    Am J Cardiol; 2007 Nov; 100(10):1499-501. PubMed ID: 17996508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study.
    Koren MJ; Hunninghake DB;
    J Am Coll Cardiol; 2004 Nov; 44(9):1772-9. PubMed ID: 15519006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.